siRNA-Polymer Conjugates for Stable Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods using viral vectors face challenges such as gene malfunction, autoimmune responses, and immune system vulnerability, while nonviral vectors like liposomes and polymers are less effective but safer and more economical, with siRNA exhibiting low stability and poor cell membrane permeability.
Innovation Solution
Conjugating siRNA with biocompatible hydrophilic polymers, specifically PEG, via a disulfide bond to enhance stability and cell delivery, forming polyelectrolyte complex micelles with cationic compounds for targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene transfer, then gene transfer efficiency is improved, but safety deteriorates due to gene malfunction, autoimmune response, and immune system vulnerability
Solution Approach 1:
The patent introduces a nonviral vector system composed of cationic polymers, liposomes, or micelles as intermediary carriers to transfer siRNA into target cells. These nonviral vectors serve as safe alternatives that mediate gene delivery without the biological hazards of viral vectors, resolving the contradiction between transfer efficiency and safety by providing a chemically-based delivery platform that avoids immunogenicity while maintaining functional capability
Solution Approach 2:
The patent modifies the chemical parameters of delivery vehicles by using synthetic cationic polymers with controlled molecular weights, charge densities, and hydrophobicity. By adjusting these chemical parameters rather than relying on biological viral structures, the system achieves effective gene transfer while eliminating the safety issues associated with viral replication and immune response
2Reliability
If nonviral vectors like liposomes and polymers are used, then safety is improved, but gene transfer efficiency deteriorates
Solution Approach 1:
The patent creates composite delivery systems by combining cationic polymers with lipids to form polyplexes or lipopolyplexes. This composite structure integrates the biocompatibility and safety of liposomes with the high charge density and transfection efficiency of cationic polymers, thereby improving gene transfer efficiency while maintaining the safety profile of nonviral vectors
Solution Approach 2:
The patent segments the delivery system into distinct functional components: a cationic polymer core for siRNA complexation and nuclear targeting, and a liposomal shell for enhanced biocompatibility and cellular uptake. This segmentation allows each component to contribute its optimal properties, resulting in improved overall efficiency while preserving safety
3Ease of operation
If siRNA is administered directly in vivo, then treatment simplicity is improved, but delivery efficiency deteriorates due to low stability and poor cell membrane permeability
Solution Approach 1:
The patent introduces cationic polymer-lipid complexes as intermediary carriers that mediate siRNA delivery across the cell membrane. These intermediaries protect siRNA from degradation in the bloodstream and facilitate its transport into cells through endocytosis, thereby improving delivery efficiency while maintaining the simplicity of systemic administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA-hydrophilic polymer conjugates improve siRNA stability and intracellular delivery, achieving specific gene silencing with reduced side effects and lower doses, effectively inhibiting target gene expression, particularly in cancer treatment.
Implementation Method 1
conjugating siRNA with biocompatible hydrophilic polymers, specifically PEG, via a disulfide bond
Implementation Method 2
polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Disclosed are hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for gene therapy in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be advantageously used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.